Safety Pharmacology of CJ-11555
![]() |
최재묵
(CJ 제약연구소)
이성학 (CJ 제약연구소) 김일환 (CJ 제약연구소) 박지은 (CJ 제약연구소) 김덕열 (CJ 제약연구소) 노현정 (CJ 제약연구소) 김택로 (CJ 제약연구소) 최광도 (CJ 제약연구소) 김영훈 (CJ 제약연구소) |
1 | 의약품 등의 일반약리시험 지침 (식품의약품 안전청 고시 제1998-62호, 1998. 5. 29 개정) |
2 | ICH Harmonized Tripartite guideline (S7A) (2001): Safety pharmacology study for human pharmaceuticals |
3 | Kang, KW., Kim, Y.G., Cho, MK, Bae, S.K., Kim, C.w., Lee, M.G. and Kim, S.G. (2002b): Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding proteinmediated stellate cell inactivation. FASEB J., 16, 1988-1990 |
4 | Irwin, S. (1968): Comprehensive observational assessment : A systemic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologica., 13, 222-257 |
5 | Hamill, O.P., Marty, A., Neher, E., Sakmann, B. and Sigworth, F.J. (1981). Improve patch clamp techniques for high-resolution current recording from cells and cell-free membrane-patches. Pflgers Arch., 391, 85-100 DOI |
6 | Ansher, S. (1985): The chemotherapy of schistosomiasis. Ann Rev Pharmacol., 25, 485-508 |
7 | Kang, K.W., Choi, S.H., Ha, J.R., Kim. C.W. and Kim, S.G. (2002a): Inhibition of dimethylnitrosamine-induced liver fibrosis by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) in rats: suppression of transforming growth factorbeta1 and tumor necrosis factor-alpha expression. Chem. Biol. Interact., 139, 61-67. |
8 | Crowell, JA, Page, J.G., Rodman, L.E., Heath, J.E., Goldenthal, E.I., Hall, L.B. and Kelloff, G.J. (1997): Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1 ,2-dithiole-3thione, a potential chemopreventive agent. Fund Appl. Toxicol., 35, 9-21 |
9 | Kensler, T.W., Egner, PA, Wang, J.B., Zhu, Y.R., Zhang, B.C., Qian, G.S., Kuang, S.Y., Gange, S.J., Jacobson, L.P., Munoz, A. and Groopman, J.D. (2002): Strategies for chemoprevention of liver cancer. Eur. J. Cancer. Prev., 2, 58-64 |
![]() |